header logo image


Page 1,448«..1020..1,4471,4481,4491,450..1,4601,470..»

An economical, effective and biocompatible gene therapy strategy promotes cardiac repair

July 6th, 2012 6:10 pm

Public release date: 6-Jul-2012 [ | E-mail | Share ]

Contact: Dr. Changfa Guo guo.changfa@zs-hospital.sh.cn Society for Experimental Biology and Medicine

Dr Changfa Guo, Professor Chunsheng Wang and their co-investigators from Zhongshan hospital Fudan University, Shanghai, China have established a novel hyperbranched poly(amidoamine) (hPAMAM) nanoparticle based hypoxia regulated vascular endothelial growth factor (HRE-VEGF) gene therapy strategy which is an excellent substitute for the current expensive and uncontrollable VEGF gene delivery system. This discovery, reported in the June 2012 issue of Experimental Biology and Medicine, provides an economical, feasible and biocompatible gene therapy strategy for cardiac repair.

Transplantation of VEGF gene manipulated mesenchymal stem cells (MSCs) has been proposed as a promising therapeutic method for cardiac repair after myocardium infarction. However, the gene delivery system, including the VEGF gene and delivery vehicle, needs to be optimized. On one hand, long-term and uncontrollable VEGF over-expression in vivo has been observed to lead to hemangioma formation instead of functional vessels in animal models. On the other hand, though non-viral gene vector can circumvent the limitations of virus, drawbacks of the current non-viral vectors, such as complex synthesis procedure, limited transfection efficiency and high cytotoxicity, still needs to be overcome.

Co-investigators, Drs. Kai Zhu and Hao Lai, said "Hypoxia response elements were inserted into the promoter region of VEGF gene to form HRE-VEGF, which provided a safer alternative to the conventionally available VEGF gene". "The HRE-VEGF up-regulates gene expression under hypoxic conditions caused by ischemic myocardium and turns it off under normoxia condition when the regional oxygen supply is adequate."

The hPAMAM nanoparticles, which exhibit high gene transfection efficiency and low cytotoxicity during the gene delivery process, can be synthesized by a simpler and more economical one-step/pot polymerization technique. Drs. Zhu and Lai, said "Using the hPAMAM based gene delivery approach, our published and unpublished results explicitly demonstrated that it was an economical, effective and biocompatible gene delivery vehicle".

Dr Guo concluded that "Treatment with hPAMAM-HRE-VEGF transfected MSCs after myocardium infarction improved the myocardial VEGF level, which improved graft MSC survival, increased neovascularization and ultimately improved heart function. And this novel VEGF gene delivery system may have clinical relevance for tissue repair in other ischemic diseases".

Dr. Steve Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Guo and colleagues have provided an exciting new nanoparticle based gene therapy for cardiac repair. This novel approach has great promise for repair of the heart after myocardial infarction."

###

Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit http://www.sebm.org. If you are interested in publishing in the journal please visit http://ebm.rsmjournals.com/

Excerpt from:
An economical, effective and biocompatible gene therapy strategy promotes cardiac repair

Read More...

Diabetes drug helps brain growth, makes mice smarter

July 6th, 2012 6:10 pm

SACRAMENTO, CA. - A drug used to treat diabetes encourages the brain to grow and repair itself, afinding with far-reaching implications for the treatment of Alzheimers and brain injury, a new study published in Cell: Stem Cell reports.

The widely used diabetes drug metformin comes with the unexpected side effect of causing the growth of new neurons in the brain and makes mice smarter, the July 6th issue of Cell Stem Cell, a Cell Press publication, said. The study has potentially wide-reaching implications for the treatment of Alzheimers in humans and brain related injury.

The discovery has important implications for brain repair because it works not by introducing new stem cells but rather by spurring those that are already present into action, said the study's lead author Freda Miller of the University of Toronto-affiliated Hospital for Sick Children. And since the drug is already so widely used and so safe it means doctors could quickly begin using the drug for brain therapy treatment.

Earlier work by Miller's team highlighted a pathway known as aPKC-CBP for its essential role in telling neural stem cells where and when to differentiate into mature neurons, the report said. Other researchers had found before them that the same pathway is important for the metabolic effects of the drug metformin, but in liver cells.

"We put two and two together," Miller says. If metformin activates the CBP pathway in the liver, they thought, maybe it could also do that in neural stem cells of the brain to encourage brain repairm, he said.

Mice taking metformin not only showed an increase in the birth of new neurons, but they proved to become smarter by being better able to learn the location of a hidden platform in a standard maze test of spatial learning. The new evidence lends support to that promising idea in both mouse brains and human cells.

While it remains to be seen whether the very popular diabetes drug might already be serving as a brain booster for those who are now taking it, there are early hints the drug may have cognitive benefits for people with Alzheimer's disease. Scientists had speculated those improvements were the result of better diabetes control, Miller says, but it now appears that metformin may improve Alzheimer's symptoms by enhancing brain repair.

Miller says they now hope to test whether metformin might help repair the brains of those who have suffered brain injury due to trauma or radiation therapies for cancer.

Original post:
Diabetes drug helps brain growth, makes mice smarter

Read More...

Diabetes drug makes brain cells grow

July 6th, 2012 6:10 pm

ScienceDaily (July 5, 2012) The widely used diabetes drug metformin comes with a rather unexpected and alluring side effect: it encourages the growth of new neurons in the brain. The study reported in the July 6th issue of Cell Stem Cell, a Cell Press publication, also finds that those neural effects of the drug also make mice smarter.

The discovery is an important step toward therapies that aim to repair the brain not by introducing new stem cells but rather by spurring those that are already present into action, says the study's lead author Freda Miller of the University of Toronto-affiliated Hospital for Sick Children. The fact that it's a drug that is so widely used and so safe makes the news all that much better.

Earlier work by Miller's team highlighted a pathway known as aPKC-CBP for its essential role in telling neural stem cells where and when to differentiate into mature neurons. As it happened, others had found before them that the same pathway is important for the metabolic effects of the drug metformin, but in liver cells.

"We put two and two together," Miller says. If metformin activates the CBP pathway in the liver, they thought, maybe it could also do that in neural stem cells of the brain to encourage brain repair.

The new evidence lends support to that promising idea in both mouse brains and human cells. Mice taking metformin not only showed an increase in the birth of new neurons, but they were also better able to learn the location of a hidden platform in a standard maze test of spatial learning.

While it remains to be seen whether the very popular diabetes drug might already be serving as a brain booster for those who are now taking it, there are already some early hints that it may have cognitive benefits for people with Alzheimer's disease. It had been thought those improvements were the result of better diabetes control, Miller says, but it now appears that metformin may improve Alzheimer's symptoms by enhancing brain repair.

Miller says they now hope to test whether metformin might help repair the brains of those who have suffered brain injury due to trauma or radiation therapies for cancer.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Read the original post:
Diabetes drug makes brain cells grow

Read More...

StemSave – Researchers Utilize Dental Stem Cells for Stroke Treatment

July 6th, 2012 6:10 pm

(PRWEB) July 05, 2012

Researchers at Adelaide University have developed a potential therapy for stroke victims utilizing dental stem cells to regenerate damaged brain cells.

The study involved the use of human dental pulp stem cells in rats suffering from post- stroke symptoms. The stem cells were transplanted into the damaged brains of the rats with the rats showing significant improvement in brain function, motor skills and cognitive abilities within several weeks. The therapy poses a new possibility for patients who have suffered a stroke. Patients will be able to use stem cells extracted from their own teeth to regenerate damaged brain tissue. The use of autologous stem cells eliminates the risk of rejection and the need for immune-suppression drugs and results in a more positive outcome. The research is so promising that the researchers hope to begin clinical trials within three to four years.

The research is another example of the inherent plasticity of dental stem cells, i.e. their ability to differentiate into a wide range of tissue types that may be utilized to treat a broad array of disease, trauma and injury. Banking your own valuable dental stem cells for use in emerging regenerative therapies is both convenient and affordable and as easy as a trip to the dentists.

To learn more about how you can bank your valuable dental stem cells , visit http://www.StemSave.com or call 877-783-6728 (877-StemSave) today.

Link:
StemSave - Researchers Utilize Dental Stem Cells for Stroke Treatment

Read More...

Stem Cells Extracted From Amniotic Fluid

July 5th, 2012 1:11 pm

July 5, 2012

Connie K. Ho for redOrbit.com Your Universe Online

Stem cell research is gaining headway, but is still controversial. Scientists hope that a new discovery regarding stem cells from amniotic fluid will pave the way to an alternative option. A collaborative group of researchers recently discovered that stem cells in amniotic fluid can be changed into a more flexible state, which could possibly open another option to embryonic stem cells.

The study was recently published in the journal Molecular Therapy and it described how a team of investigators from Imperial College London and the UCL Institute of Child Health were successful in reprogramming amniotic fluids without introducing extra genes. Based on the findings, the researchers believe that stem cells from amniotic fluid could be held in banks for therapy or research purposes. Amniotic fluid, which surrounds and feeds the fetus, can be taken from the mothers abdomen with a needle during amniocentesis and has stem cells from the fetus. These stem cells have more limitations in developing into other cells as compared to embryonic stem cells.

These cells have a wide range of potential applications in treatments and in research. We are particularly interested in exploring their use in genetic diseases diagnosed early in life or other diseases such as cerebral palsy, noted Dr. Pascale Guillot, a representative of the Department of Surgery and Cancer at Imperial College London, in a prepared statement.

In the project, the scientists utilized stem cells that were donated from mothers who were undergoing amniocentesis; amniocentesis has been used in the past in testing for genetic diseases. The cells were then grown on a gelatinous protein mixture in a lab and reprogrammed into a lower state by adding the drug valproic acid to the culture medium. The results showed that the reprogrammed cells had traits like those found in embryonic stem cells; embryonic stem cells have pluripotency, which means they have the ability to develop into any cell type found in the body. In particular, the reprogrammed cells from the amniotic fluid were able to develop into functioning cells like bone, liver, and nerve cells. The cells were also able to stay pluripotent after they were frozen and rethawed.

Amniotic fluid stem cells are intermediate between embryonic stem cells and adult stem cells. They have some potential to develop into different cell types but they are not pluripotent. Weve shown that they can revert to being pluripotent just by adding a chemical reagent that modifies the configuration of the DNA so that genes that are expressed in the embryo get switched back on, explained Guillot in the statement.

The findings from the project showed that stem cells from amniotic fluid can possibly be used in treatments for a number of diseases, disease research, and drug screenings. Researchers are positive about the alternative to embryonic stem cells, as it there is a limited number of donor embryos available. The study by Guillot and his colleagues shows that it is possible to have pluripotency in human cells without introducing foreign genetic material into the cells.

This study confirms that amniotic fluid is a good source of stem cells. The advantages of generating pluripotent cells without any genetic manipulation make them more likely to be used for therapy, remarked Dr. Paolo De Coppi, a member of the UCL Institute of Child Health who led the research with Guillot, in the statement. At GOSH we have focused on building organs and tissues for the repair of congenital malformations, which are usually diagnosed during pregnancy. Finding the way of generating pluripotent cells from the fluid that surround the fetus in the womb move us one step further in the this direction.

The study is funded by the Genesis Research Trust, the Henry Smith Charity, and the Action Medical Research.

Follow this link:
Stem Cells Extracted From Amniotic Fluid

Read More...

PNAS Publishes OncoMed Data Demonstrating Potent Anti-Cancer Activity for Novel Wnt Pathway Antibody OMP-18R5

July 4th, 2012 8:17 am

REDWOOD CITY, Calif.--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) July 2, 2012 PNAS Early Edition has published online OncoMed data demonstrating the potent anti-cancer activity of OMP-18R5, the companys first Wnt pathway product candidate, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.

OMP-18R5 is, we believe, the first therapeutic antibody to enter clinical trials that specifically inhibits the Wnt pathway, an important pathway in cancer. Our research published in PNAS suggests that inhibiting the Wnt pathway within tumors has the potential to improve treatment for multiple cancers, said Austin Gurney, Ph.D., Senior Vice President, Molecular and Cellular Biology of OncoMed Pharmaceuticals and a co-author of the paper. OMP-18R5 has demonstrated the remarkable ability to drive the differentiation of tumor cells in preclinical models. Tumors become less tumorigenic.

The Wnt/beta-catenin pathway, which signals through the Frizzled (Fzd) receptor family and several co-receptors, has long been implicated in cancer. OncoMed researchers identified a novel therapeutic approach to targeting the Wnt pathway with a monoclonal antibody. OMP-18R5, initially identified by binding to Frizzled 7, interacts with key Fzd receptors through a conserved epitope within the extracellular domain and thereby inhibits canonical Wnt signaling induced by multiple Wnt family members. In xenograft studies with minimally passaged human tumors, OMP-18R5 inhibits the growth of a range of tumor types and exhibits synergistic activity with standard-of-care chemotherapeutic agents. These data are published in current edition of PNAS in an article titled Wnt Pathway Inhibition via the Targeting of Frizzled Receptors Results in Decreased Growth and Tumorigenicity of Human Tumors.

Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals, said, OMP-18R5 is among a rich pipeline of therapeutic candidates discovered by OncoMed that are now in clinical trials. We look forward to reporting results from our initial trials as this product advances through the clinic.

About OMP-18R5

OMP-18R5 is a monoclonal antibody optimized to block a key signaling pathway in cancer. Specifically, OMP-18R5 selectively targets Frizzled receptors, activators of Wnt signaling. OMP-18R5 treatment exhibits broad anti-tumor activity in preclinical models. OMP-18R5 is currently in a Phase 1 clinical trial in patients with advanced solid tumors. This trial will assess safety, pharmacokinetics, and provide initial indications of anti-tumor efficacy and the effects of OMP-18R5 on Wnt pathway biomarkers. OMP-18R5 is part of OncoMeds collaboration with Bayer Pharma AG.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells shown to be capable of driving tumor growth, recurrence and metastasis. OncoMed has advanced three anti-cancer therapeutics into the clinic, demcizumab (OMP-21M18), OMP-59R5, and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMeds pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways, including the RSPO-LGR pathway. OncoMed has formed strategic alliances with Bayer Pharma AG and GlaxoSmithKline. Privately held, OncoMeds investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the companys website: http://www.oncomed.com.

Follow this link:
PNAS Publishes OncoMed Data Demonstrating Potent Anti-Cancer Activity for Novel Wnt Pathway Antibody OMP-18R5

Read More...

Amniotic fluid yields alternatives to embryonic stem cells

July 4th, 2012 8:17 am

ScienceDaily (July 3, 2012) Stem cells found in amniotic fluid can be transformed into a more versatile state similar to embryonic stem cells, according to a study published July 3 in the journal Molecular Therapy. Scientists from Imperial College London and the UCL Institute of Child Health succeeded in reprogramming amniotic fluid cells without having to introduce extra genes. The findings raise the possibility that stem cells derived from donated amniotic fluid could be stored in banks and used for therapies and in research, providing a viable alternative to the limited embryonic stem cells currently available.

Amniotic fluid surrounds and nourishes the fetus in the womb. It can be extracted through the mother's abdomen using a needle in a process called amniocentesis, which is sometimes used to test for genetic diseases. The fluid contains stem cells that come from the fetus. These cells have a more limited capacity to develop into different cell types than stem cells in the embryo.

The researchers used stem cells from amniotic fluid donated by mothers undergoing amniocentesis for other purposes during the first trimester of pregnancy. The cells were grown on a gelatinous protein mixture in the lab and reprogrammed into a more primitive state by adding a drug called valproic acid to the culture medium. An extensive set of tests found that these reprogrammed cells have characteristics very similar to embryonic stem cells, which are capable of developing into any cell type in the body -- a property known as pluripotency.

Even after growing in culture for some time, the reprogrammed cells were able to develop into functioning cells of many different types, including liver, bone and nerve cells. They also maintained their pluripotency even after being frozen and rethawed.

The results suggest that stem cells derived from amniotic fluid could be used in treatments for a wide range of diseases. Donated cells could be stored in banks and used in treatments, as well as in disease research and drug screening. A previous study estimated that cells from 150 donors would provide a match for 38% of the population.

Alternatives to embryonic stem cells are keenly sought because of ethical concerns and limited availability of donor embryos. Previous research has shown that it is possible to make adult cells become pluripotent by introducing extra genes into the cells, often using viruses. However, the efficiency of the reprogramming is very low and there is a risk of problems such as tumours caused by disrupting the DNA. The new study is the first to induce pluripotency in human cells without using foreign genetic material. The pluripotent cells derived from amniotic fluid also showed some traits associated with embryonic stem cells that have not been found in induced pluripotent stem cells from other sources.

Amniocentesis is associated with a small risk of causing a miscarriage, estimated to be about one in 100.

Dr Pascale Guillot, from the Department of Surgery and Cancer at Imperial, said: "Amniotic fluid stem cells are intermediate between embryonic stem cells and adult stem cells. They have some potential to develop into different cell types but they are not pluripotent. We've shown that they can revert to being pluripotent just by adding a chemical reagent that modifies the configuration of the DNA so that genes that are expressed in the embryo get switched back on.

"These cells have a wide range of potential applications in treatments and in research. We are particularly interested in exploring their use in genetic diseases diagnosed early in life or other diseases such as cerebral palsy."

Dr Paolo De Coppi, from the UCL Institute of Child Health, who jointly led the study with Dr Guillot, said: "This study confirms that amniotic fluid is a good source of stem cells. The advantages of generating pluripotent cells without any genetic manipulation make them more likely to be used for therapy.

Original post:
Amniotic fluid yields alternatives to embryonic stem cells

Read More...

Adult stem cells from bone marrow: Cell replacement/tissue repair potential in adult bone marrow stem cells in animal …

July 4th, 2012 8:17 am

ScienceDaily (July 3, 2012) searchers from the University of Maryland School of Maryland report promising results from using adult stem cells from bone marrow in mice to help create tissue cells of other organs, such as the heart, brain and pancreas -- a scientific step they hope may lead to potential new ways to replace cells lost in diseases such as diabetes, Parkinson's or Alzheimer's.

The research in collaboration with the University of Paris Descartes is published online in the June 29, 2012 edition of Comptes Rendus Biologies, a publication of the French Academy of Sciences.

"Finding stem cells capable of restoring function to different damaged organs would be the Holy Grail of tissue engineering," says lead author David Trisler, PhD, assistant professor of neurology at the University of Maryland School of Medicine.

He adds, "This research takes us another step in that process by identifying the potential of these adult bone marrow cells, or a subset of them known as CD34+ bone marrow cells, to be 'multipotent,' meaning they could transform and function as the normal cells in several different organs."

University of Maryland researchers previously developed a special culturing system to collect a select sample of these adult stem cells in bone marrow, which normally makes red and white blood cells and immune cells. In this project, the team followed a widely recognized study model, used to prove the multipotency of embryonic stem cells, to prove that these bone marrow stem cells could make more than just blood cells. The investigators also found that the CD34+ cells had a limited lifespan and did not produce teratomas, tumors that sometimes form with the use of embryonic stem cells and adult stem cells cultivated from other methods that require some genetic manipulation.

"When taken at an early stage, we found that the CD34+ cells exhibited similar multipotent capabilities as embryonic stem cells, which have been shown to be the most flexible and versatile. Because these CD34+ cells already exist in normal bone marrow, they offer a vast source for potential cell replacement therapy, particularly because they come from a person's own body, eliminating the need to suppress the immune system, which is sometimes required when using adults stem cells derived from other sources," explains Paul Fishman, MD, PhD, professor of neurology at the University of Maryland School of Medicine.

The researchers say that proving the potential of these adult bone marrow stem cells opens new possibilities for scientific exploration, but that more research will be needed to see how this science can be translated to humans.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

See the original post here:
Adult stem cells from bone marrow: Cell replacement/tissue repair potential in adult bone marrow stem cells in animal ...

Read More...

Study Results: Adult Stem Cells From Bone Marrow

July 4th, 2012 8:17 am

FOR IMMEDIATE RELEASE: July 3, 2012

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE INVESTIGATORS FIND CELL REPLACEMENT/ TISSUE REPAIR POTENTIAL IN ADULT BONE MARROW STEM CELLS IN ANIMAL MODEL

Scientists Looking for Potential Avenue to Grow Cells of Different Organs

Newswise Baltimore, MD July 3, 2012. Researchers from the University of Maryland School of Maryland report promising results from using adult stem cells from bone marrow in mice to help create tissue cells of other organs, such as the heart, brain and pancreas - a scientific step they hope may lead to potential new ways to replace cells lost in diseases such as diabetes, Parkinsons or Alzheimers. The research in collaboration with the University of Paris Descartes is published online in the June 29, 2012 edition of Comptes Rendus Biologies, a publication of the French Academy of Sciences.

Finding stem cells capable of restoring function to different damaged organs would be the Holy Grail of tissue engineering, says lead author David Trisler, PhD, assistant professor of neurology at the University of Maryland School of Medicine.

He adds, This research takes us another step in that process by identifying the potential of these adult bone marrow cells, or a subset of them known as CD34+ bone marrow cells, to be multipotent, meaning they could transform and function as the normal cells in several different organs.

University of Maryland researchers previously developed a special culturing system to collect a select sample of these adult stem cells in bone marrow, which normally makes red and white blood cells and immune cells. In this project, the team followed a widely recognized study model, used to prove the multipotency of embryonic stem cells, to prove that these bone marrow stem cells could make more than just blood cells. The investigators also found that the CD34+ cells had a limited lifespan and did not produce teratomas, tumors that sometimes form with the use of embryonic stem cells and adult stem cells cultivated from other methods that require some genetic manipulation.

When taken at an early stage, we found that the CD34+ cells exhibited similar multipotent capabilities as embryonic stem cells, which have been shown to be the most flexible and versatile. Because these CD34+ cells already exist in normal bone marrow, they offer a vast source for potential cell replacement therapy, particularly because they come from a persons own body, eliminating the need to suppress the immune system, which is sometimes required when using adults stem cells derived from other sources, explains Paul Fishman, MD, PhD, professor of neurology at the University of Maryland School of Medicine.

The researchers say that proving the potential of these adult bone marrow stem cells opens new possibilities for scientific exploration, but that more research will be needed to see how this science can be translated to humans.

The results of this international collaboration show the important role that University of Maryland School of Medicine researchers play in advancing scientific understanding, investigating new avenues for the development of potentially life-changing treatments, says E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of the University of Maryland School of Medicine.

Read more:
Study Results: Adult Stem Cells From Bone Marrow

Read More...

Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of …

July 4th, 2012 8:17 am

BELGRADE, Mont., July 3, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT LLC: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, received a letter from NYSE Regulation on July 2, 2012 advising that the Company did not comply with Sections 703 and 1009 of the NYSEMKT LLC Company Guide, which required the Company to provide the NYSEMKT LLC with ten days prior notice of the June 8, 2012 record date for its upcoming 2012 Annual Meeting of Stockholders. The Company will file a Form 8-K with the Securities and Exchange Commission related to this matter. The NYSE MKT LLC also notified the Company that according to Section 401(j) of the Company Guide it needed to issue a news release. This action will NOT result in the suspension or delisting of the Company's securities.

About Bacterin International Holdings Bacterin International Holdings, Inc. (NYSE MKT LLC: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit http://www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

INVESTOR INQUIRIES: Hayden IR James Carbonara, Regional Vice President, 646-755-7412 james@haydenir.com

Brett Maas, 646-536-7331 brett@haydenir.com

See the original post here:
Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of ...

Read More...

Ireland could be stem cell research hub

July 4th, 2012 8:14 am

Tuesday, July 03 16:25:12

Ireland has the capacity to be an international centre for commercialisation in the field of regenerative medicine, delegates at an international stem cell conference in NUI Galway heard today.

Reflecting this potential, new Irish company Orbsen Therapeutics is developing proprietary technologies designed to isolate stem cells. The NUI Galway spin-out is targeting the rapidly maturing and expanding regenerative medicine market, which is expected to grow to $118 billion next year.

Frank Barry is Professor of Cellular Therapy at NUI Galway, Director of Orbsen Therapeutics, and organiser of the Mesenchymal Stem Cell Conference, which opened yesterday.

Mesenchymal stem cells (MSCs) are a type of adult stem cell, and this event brings together the world's leading scientists in the field to discuss their latest ideas and findings. This is the first major stem cell conference to take place in Ireland, and is looking at all aspects of adult stem cells, from basic biology to manufacturing to clinical trials and therapeutics.

Stem cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment potential of stem cells is linked to their natural capacity to dampen inflammation and promote healing, repair and regeneration of damaged tissues.

According to Professor Barry: "Ireland has a strong research base in adult stem cell therapy and has the capcacity for advanced stem cell bioprocessing. There is huge potential in this market and we anticipate that there will be extraordinary growth over the next 5-10 years. There are currently over 400 regenerative medicine products on the market with many more in development." Orbsen Therapeutics has developed a clear pipeline of clinical indications which they hope, using their proprietary technologies, to bring through to clinical trial over the coming years. These include osteoarthritis, acute lung injury syndrome, diabetic foot ulcer, critical limb ischemia and others."

"Combining the utility, novelty and the value of its technologies, Orbsen is well placed to take advantage of the many opportunities in this fast moving and important emerging market", said Brian Molloy, CEO of Orbsen Theraepeutics."

Orbsen Therapeutics Limited was formed as a spin out company to develop and commercialise new intellectual property built up by researchers at the SFI-funded Regenerative Medicine Institute (REMEDI) at NUI Galway.

Scientists at NUI Galway are investigating how adult stems cells might be used to develop new treatments for vascular disease, osteoarthritis and lung injury. The University has become a leading centre of translational research in adult stem cells involving its National Centre for Biomedical Engineering Science (NCBES) and REMEDI.

More here:
Ireland could be stem cell research hub

Read More...

Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis

July 4th, 2012 8:14 am

SHENZHEN, China, July 3, 2012 /PRNewswire-Asia/-- A study conducted by Beike Biotechnology Company (http://www.beikebiotech.com) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind. Researchers noted that additional clinical trials would be required before stem cells can become an accepted therapy for liver cirrhosis.

Prof. Jin-hui Yang, Director of the Department of Hepatology in the 2nd Affiliated Hospital of Kunming Medical College stated, "Given the severity of liver cirrhosis and its related conditions, and the limited number of options available to treat those who suffer from it, this finding represents an important, potentially significant breakthrough."

PBC is a chronic, progressive liver disease that leads eventually to fibrosis and cirrhosis of the liver. It affects 1 in 1,000 women over the age of 40.Approximately one-third of those who suffer from PBC and its related conditions do not respond well to Ursodeoxycholic acid (UDCA) treatment, which is the only currently FDA-approved standard medical treatment for the condition. Many of those patients ultimately require liver transplantation.

Beike Chairman, Dr. Sean Hu, commented, "With a growing body of research that demonstrates the effectiveness of cord blood-derived stem cell therapies in treating a broad range of chronic conditions, this latest study is a milestone in the continuing effort to gain broad acceptance and recognition of regenerative medicine as a mainstream treatment option.We look forward to conducting more comprehensive clinical trials to attempt to validate the positive outcomes we have already observed."

The case study reported in the Stem Cell Discovery involved a 58 year old woman suffering from PBC who developed an incarcerated hernia and uncontrolled hydrothorax after undergoing UDCA treatment.One week after completing two stem cell transplantations with no observed adverse effects, the patient showed improvement in both liver function and in her general condition. She was released from the hospital but continued to receive twice-daily UDCA treatments. Six months after her discharge, doctors observed continued improvements in her liver function and overall condition.

To review the full text of the published study, please visit: http://www.scirp.org/journal/PaperInformation.aspx?paperID=18710. Study authors included physicians and researchers from the 2nd Affiliated Hospital of Kunming Medical College, Beike Biotechnology Company, and the Yunnan Provincial 1st People's Hospital in Kunming, China.

About Beike Biotechnology Company

Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on the production of adult stem cells for use in medical therapies. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.

For any questions regarding this release, please call:

Contact Person: T. Gutmann Phone Number: +86-532-6677-6659

Read the original here:
Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis

Read More...

Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy …

July 3rd, 2012 6:19 pm

TAMPA, Fla., July 3, 2012 /PRNewswire/ --On behalf of Saneron CCEL Therapeutics, Inc., President and COO, Nicole Kuzmin-Nichols, MBA, expressed strong support today for the Cryo-Cell International, Inc. (CCEL) current executive management in response to a proxy bid by a former Board member. Cryo-Cell is a major shareholder in Saneron, a Tampa based biotechnology research and development company that was spun out from the University of South Florida to develop cellular therapies for deadly diseases that lack adequate treatment options.

"Saneron has enjoyed a good working relationship with David and Mark Portnoy since they assumed leadership at Cryo-Cell in August 2011, and our board is convinced that their guidance is adding shareholder value," commented Kuzmin-Nichols. "They have shown themselves to be committed partners with Saneron as we continue breaking new ground in cord and menstrual blood stem cell research. Our Small Business Technology Transfer Program (STTR) Phase II efforts are producing real progress towards effective treatments for Alzheimer's disease and stroke and we look forward to continuing our research in concert with Cryo-Cell."

"Our research team is very impressed with Dr. Linda Kelley, Cryo-Cell's new chief scientific officer, who joined the company from Harvard's Dana-Farber Cancer Institute. She will be a valuable collaborator. The Portnoys' ability to attract such top notch talent speaks volumes about their clear vision for the company's future and commitment to keeping it on the leading edge of regenerative medicine," she continued.

"Mark and David Portnoy have made great strides in establishing strong relationships with obstetricians and gynecologists to enhance patient awareness of Cryo-Cell. Our team has worked hand in hand with them to inform physicians about the latest developments in cord blood and cord tissue stem cell research so the physicians understand how important it is to encourage expectant parents to store their cord blood and cord tissue. During the 11 years that Saneron and Cryo-Cell have been associated, this is the first time we've seen Cryo-Cell reach out so assertively to the core physicians who have the ability to create streams of revenue for the company. We couldn't be more pleased to be working with David, Mark and their team as they take the company to the next level. Shareholders would be wise to retain them."

About Saneron CCEL Therapeutics, Inc. Saneron CCEL Therapeutics, Inc. is a biotechnology research and development company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases which lack adequate treatment options. Saneron, a University of South Florida spin-out company, is located at the Tampa Bay Technology Incubator. Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to its platform technology of umbilical cord blood and Sertoli cells.

http://www.saneron-ccel.com

http://www.cryo-cell.com

Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

See the rest here:
Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy ...

Read More...

Ireland could be stem cell research hub

July 3rd, 2012 6:19 pm

Tuesday, July 03 16:25:12

Ireland has the capacity to be an international centre for commercialisation in the field of regenerative medicine, delegates at an international stem cell conference in NUI Galway heard today.

Reflecting this potential, new Irish company Orbsen Therapeutics is developing proprietary technologies designed to isolate stem cells. The NUI Galway spin-out is targeting the rapidly maturing and expanding regenerative medicine market, which is expected to grow to $118 billion next year.

Frank Barry is Professor of Cellular Therapy at NUI Galway, Director of Orbsen Therapeutics, and organiser of the Mesenchymal Stem Cell Conference, which opened yesterday.

Mesenchymal stem cells (MSCs) are a type of adult stem cell, and this event brings together the world's leading scientists in the field to discuss their latest ideas and findings. This is the first major stem cell conference to take place in Ireland, and is looking at all aspects of adult stem cells, from basic biology to manufacturing to clinical trials and therapeutics.

Stem cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment potential of stem cells is linked to their natural capacity to dampen inflammation and promote healing, repair and regeneration of damaged tissues.

According to Professor Barry: "Ireland has a strong research base in adult stem cell therapy and has the capcacity for advanced stem cell bioprocessing. There is huge potential in this market and we anticipate that there will be extraordinary growth over the next 5-10 years. There are currently over 400 regenerative medicine products on the market with many more in development." Orbsen Therapeutics has developed a clear pipeline of clinical indications which they hope, using their proprietary technologies, to bring through to clinical trial over the coming years. These include osteoarthritis, acute lung injury syndrome, diabetic foot ulcer, critical limb ischemia and others."

"Combining the utility, novelty and the value of its technologies, Orbsen is well placed to take advantage of the many opportunities in this fast moving and important emerging market", said Brian Molloy, CEO of Orbsen Theraepeutics."

Orbsen Therapeutics Limited was formed as a spin out company to develop and commercialise new intellectual property built up by researchers at the SFI-funded Regenerative Medicine Institute (REMEDI) at NUI Galway.

Scientists at NUI Galway are investigating how adult stems cells might be used to develop new treatments for vascular disease, osteoarthritis and lung injury. The University has become a leading centre of translational research in adult stem cells involving its National Centre for Biomedical Engineering Science (NCBES) and REMEDI.

View post:
Ireland could be stem cell research hub

Read More...

Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis

July 3rd, 2012 6:19 pm

SHENZHEN, China, July 3, 2012 /PRNewswire-Asia/-- A study conducted by Beike Biotechnology Company (http://www.beikebiotech.com) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind. Researchers noted that additional clinical trials would be required before stem cells can become an accepted therapy for liver cirrhosis.

Prof. Jin-hui Yang, Director of the Department of Hepatology in the 2nd Affiliated Hospital of Kunming Medical College stated, "Given the severity of liver cirrhosis and its related conditions, and the limited number of options available to treat those who suffer from it, this finding represents an important, potentially significant breakthrough."

PBC is a chronic, progressive liver disease that leads eventually to fibrosis and cirrhosis of the liver. It affects 1 in 1,000 women over the age of 40.Approximately one-third of those who suffer from PBC and its related conditions do not respond well to Ursodeoxycholic acid (UDCA) treatment, which is the only currently FDA-approved standard medical treatment for the condition. Many of those patients ultimately require liver transplantation.

Beike Chairman, Dr. Sean Hu, commented, "With a growing body of research that demonstrates the effectiveness of cord blood-derived stem cell therapies in treating a broad range of chronic conditions, this latest study is a milestone in the continuing effort to gain broad acceptance and recognition of regenerative medicine as a mainstream treatment option.We look forward to conducting more comprehensive clinical trials to attempt to validate the positive outcomes we have already observed."

The case study reported in the Stem Cell Discovery involved a 58 year old woman suffering from PBC who developed an incarcerated hernia and uncontrolled hydrothorax after undergoing UDCA treatment.One week after completing two stem cell transplantations with no observed adverse effects, the patient showed improvement in both liver function and in her general condition. She was released from the hospital but continued to receive twice-daily UDCA treatments. Six months after her discharge, doctors observed continued improvements in her liver function and overall condition.

To review the full text of the published study, please visit: http://www.scirp.org/journal/PaperInformation.aspx?paperID=18710. Study authors included physicians and researchers from the 2nd Affiliated Hospital of Kunming Medical College, Beike Biotechnology Company, and the Yunnan Provincial 1st People's Hospital in Kunming, China.

About Beike Biotechnology Company

Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on the production of adult stem cells for use in medical therapies. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.

For any questions regarding this release, please call:

Contact Person: T. Gutmann Phone Number: +86-532-6677-6659

Read this article:
Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis

Read More...

Cryo-Save´s Cost-Free Donation Programme Serves Families in Need

July 3rd, 2012 1:20 pm

ZUTPHEN, The Netherlands, July 3, 2012 /PRNewswire/ --

Free of charge, Cryo-Saves programme gives the opportunity to treat a family member diagnosed with a life-threatening disease treatable with stem cells.

Cryo-Save, the leading international family stem cell bank, shows continuous commitment to its corporate social responsibility programme. Family and childrens health is the companys number one priority. The Cryo-Save Cost-Free Family Donation Programme is specifically designed to offer families in need the collection and cryopreservation of their newborns umbilical cord blood stem cells. Free of charge, it gives the opportunity to treat a family member diagnosed with a life-threatening disease treatable with stem cells. This includes diseases such as Sickle Cell Anaemia and some forms of Leukaemia.

Arnoud van Tulder, CEO of Cryo-Save: "Our goal is to help as many families as possible with the stem cells they store with Cryo-Save. Through our Cost-Free Donation Programme, we offer direct help to families in need. This is very important for us; being able to apply our knowledge and expertise to help save lives!"

Thanks to Cryo-Saves international reach and more than 40 local offices which are in touch with their communities needs, each country is striving to make a positive difference in their community. The Cost-Free Donation Programme is promoted in each country. Among other activities, the company recently supported two fundraising events: Cryo-Saves Netherlands office sponsored a cycling event organised by the Alpe dHuZes Cancer Rehabilitation (A-CaRe) programme, which aims to develop and implement rehabilitation programmes for specific cancer patients and survivor groups in the Netherlands. Cryo-Save Serbia is supporting the NGO Everything for a Smile where children suffering from renal diseases are invited to enjoy a rare weekend in nature.

Along with its continuous efforts to educate the general public about stem cells, Cryo-Save strives to make a difference in peoples lives and encourages all its employees to consider the impact their work makes on the environment and local communities.

Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on three continents, with ultra-modern processing and storage facilities in Arabia, Belgium, Germany, India and South Africa.

Cryo-Save: http://www.cryo-save.com/group

Cryo-Save Group N.V.

Read the original post:
Cryo-Save´s Cost-Free Donation Programme Serves Families in Need

Read More...

Mel Gibson's Step-Mom Files For Restraining Order Against The Star

July 3rd, 2012 1:19 pm

07/03/2012 . (TMZ) Mel Gibson THREATENED his own 78-year-old step-mom ... SPIT IN HER FACE ... and sabotaged her marriage ... this according to legal docs filed by the woman and obtained by TMZ.

Teddy Joye Hicks Gibson -- who married Mel's father Hutton Gibson in 2001 -- has filed for a restraining order against Mel ... claiming he exploded on her several times and now she fears for her safety.

In the docs, Joye claims Mel and his sister Maura hate her guts ... because she doesn't approve of the controversial medical treatments they've been pressuring Hutton to undergo to treat his various ailments.

In the docs, filed by attorney Brian J. Kramer, Joye describes several outbursts in detail:

October 2011 -- Mel screams at Joye because Joye does not approve of "experimental Ozone treatments" Hutton was undergoing for an undisclosed illness.

"Mel began yelling and saying, 'f*ck this and f*ck that' while leveling other extremely offensive language at me."

Joye claims Mel warned her "not to f*ck with [Hutton's] treatments in any way."

January 2012 -- While visiting Hutton in the hospital, Joye claims she said something that set Mel off ... and "Mel got up, looking wild and began yelling at me in a very loud and terrifying voice."

"Mel was so upset and screaming so fiercely that I could see his face turn red."

March 2012 -- Joye, along with Mel and his sister Maura, accompanied Hutton to Panama for stem cell treatment for his hip.

Follow this link:
Mel Gibson's Step-Mom Files For Restraining Order Against The Star

Read More...

Mrs. Itana, a diabetic nephropathy from Papua New Guinean for Stem Cells and TCM Treatment – Video

July 3rd, 2012 1:19 pm

02-07-2012 21:07 Mrs Itana was diagnosed with diabetic nephropathy 15 years ago and in February, 2012 she was told by her doctor her kidneys did not work well and dialysis was necessary. Before she came to China for STEM CELL and TRANDITIONAL CHINESE MEDICINE TREATMENT, she was hospitalized in local couple of times because she was very weak and had short of breath, heart failure and so many. After the first stem cells transplant, she felt she was back 16 years old person and so energetic. Therefore, she wants to share his treatment experiences to all kidney disease patients and wish her words and successful experience can be widely spread out. And, more of the cancer patients can seek for the proper treatment in China. And yet, in her country Mrs Itana only has one choice -- kidney transplant.

Visit link:
Mrs. Itana, a diabetic nephropathy from Papua New Guinean for Stem Cells and TCM Treatment - Video

Read More...

ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial

July 3rd, 2012 6:11 am

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardts macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, June 29 at Moorfields Eye Hospital in London, the same site as the first patient treatment in January, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The procedure was successfully performed without any complications. ACT and Moorfields Eye Hospital recently received clearance from the Data and Safety Monitoring Board (DSMB) to treat the final two patients in the first cohort of this clinical trial.

We are very pleased to continue our forward momentum with both our U.S. trials and our European trial, commented Gary Rabin, chairman and CEO. It was less than a month ago that we received DSMB approval to treat the second and third patients in our E.U. trial, and it is very gratifying to have already completed dosing of the second. It is a pleasure to be working with Professor Bainbridge and the rest of his team at Moorfields Eye Hospital, and we continue to be encouraged by the steady progress of the trial thus far.

The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the studys primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.

The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of Stargardt's Macular Dystrophy (SMD).

More information on the status of the companys clinical trials will be posted today on Mr. Rabins Chairmans blog.

About Stargardts Disease Stargardts disease or Stargardts Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.

About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Read more:
ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial

Read More...

SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video

July 3rd, 2012 6:10 am

02-07-2012 09:43 State of the Nation is a nightly newscast anchored by award-winning broadcast journalist, Jessica Soho. It airs Mondays to Fridays at 9:00 PM (PHL Time) on GMA News TV Channel 11. For more videos from State of the Nation, visit fthenation.

Read the rest here:
SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan - Video

Read More...

Page 1,448«..1020..1,4471,4481,4491,450..1,4601,470..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick